Results 101 to 110 of about 23,498 (195)

Natalizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Neurology and Therapy
Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient preference ...
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky   +15 more
doaj   +1 more source

A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Annals of Clinical and Translational Neurology
Objective No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available.
Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio, Matilde Inglese, Matteo Foschi, Francesco Patti, Franco Granella, Silvia Romano, Paola Cavalla, Giovanna De Luca, Paolo Gallo, Paolo Bellantonio, Antonio Gallo, Sara Montepietra, Alessia Di Sapio, Marika Vianello, Rocco Quatrale, Daniele Spitaleri, Raffaella Clerici, Valentina Torri Clerici, Eleonora Cocco, Vincenzo Brescia Morra, Girolama Alessandra Marfia, Vincenzo Daniele Boccia, Massimo Filippi, Maria Pia Amato, Maria Trojano, the Italian MS Register   +29 more
doaj   +1 more source

In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy in patients with multiple sclerosis

Nature Communications
Despite the efficacy of natalizumab, which targets the integrin VLA-4, in treating multiple sclerosis (MS), approximately 35% patients with MS present evidence of disease activity two years after treatment initiation.
Beatriz Chaves, Juan Carlo Santos e Silva, Helder Nakaya, Nicolas Socquet-Juglard, Florence Bucciarelli, Guilhèn Prunier, Matheus V. Almeida, Claire Lacouture, Saniya Kari, Anne L. Astier, Marco A. Medeiros, João H. M. Silva, Roland Liblau, Vinicius Cotta-de-Almeida, Loïc Dupré   +14 more
doaj   +1 more source

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab fingolimod efficacy in multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2018
Background: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the ‘no evidence of disease activity’ (NEDA) definition should now include CLs.
Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki, Lisa Federle, Erica Stropparo, Mariagiulia Anglani, Francesca Rinaldi, Paola Perini, Paolo Gallo   +8 more
doaj   +1 more source

Impacto del Natalizumab sobre la población linfocitaria B: un estudio retrospectivo [PDF]

, 2014
La esclerosis múltiple es una compleja enfermedad del Sistema Nervioso Central, caracterizada por una progresiva desmielinizacion del los axones del SNC y de la corteza espinal.
Garonna, Sebastiano
core   +1 more source

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US

ClinicoEconomics and Outcomes Research, 2013
Machaon M Bonafede,1 Barbara H Johnson,1 Crystal Watson2 1Truven Health Analytics, Cambridge, MA, USA; 2Biogen Idec, Weston, MA, USA Objectives: To evaluate multiple sclerosis (MS)-related health care-resource utilization and costs prior to and after ...
Bonafede MM, Johnson BH, Watson C
doaj  

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis [PDF]

, 2017
Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of relapsing-remitting multiple sclerosis (RRMS). Understanding the impact of different disease modifying therapies on the CSF biomarker profile may increase their ...
Axelsson, M, Blennow, K, Khademi, M, Lycke, J, Malmeström, C, Novakova, L, Olsson, T, Piehl, F, Zetterberg, H   +8 more
core  

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Therapeutic Advances in Neurological Disorders
Background: Aggressive disease control soon after multiple sclerosis (MS) diagnosis may prevent irreversible neurological damage, and therefore early initiation of a high-efficacy disease-modifying therapy (DMT) is of clinical relevance.
Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan, Tim Spelman,   +18 more
doaj   +1 more source

The wearing-off effect with natalizumab: Back to the drawing board. [PDF]

Neurotherapeutics
Afzal S, Conway DS.
europepmc   +1 more source